**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 17966**

**Manuscript Type: META-ANALYSIS**

**glutathione S-transferase M1 polymorphism and** **esophageal** **cancer risk: An updated meta-analysis based on 37 studies**

Lu QJ *et al*. GSTM1 and esophageal cancer risk: A meta-analysis

Quan-Jun Lu, Ya-Cong Bo, Yan Zhao, Er-Jiang Zhao, Wolde Bekalo Sapa, Ming-Jie Yao, Dan-Dan Duan, Yi-Wei Zhu, Wei-Quan Lu, Ling Yuan

**Quan-Jun Lu, Ya-Cong Bo,** **Wolde Bekalo Sapa, Dan-Dan Duan, Yi-Wei Zhu,** Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China

**Yan Zhao,** Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China

**Er-Jiang Zhao, Wei-Quan Lu,** Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, Zhengzhou 450003, Henan Province, China

**Ming-Jie Yao,** School of Basic Medical Sciences, Peking University Beijing, Beijing 100191, China

**Ling Yuan,** Department of Radiotherapy, Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, Zhengzhou 450003, Henan Province, China

**Author contributions:** Yuan L, Lu QJ and Lu WQ conceived and designed the experiments; Zhao Y, Zhao EJ, Bo YC, Duan DD and Zhu YW selected the experiments, extracted the data and performed the statistical analysis; Lu QJ and Bo YC drafted the manuscript; sapa WB and Yao MJ revised the manuscript.

**Supported by** Science and Technology Project of The Health Department of Henan Province, China, No. 510102050432.

**Conflict-of-interest statement:** The authors declare that there are no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article selected by an in-house editor and fully peer-reviewed by external reviewers. This article is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, and build upon this work non-commercially and license the derivative works on different terms, provided that the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

**Correspondence to**: **Ling Yuan,** **M****D,**Department of Radiotherapy, Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, No. 1 Jianshe East Rd, Erqi District, Zhengzhou 450003, Henan Province, China. hnyl2001@126.com

**Telephone:** +86-371-67781868

**Fax:** +86-371-67781868

**Received:** March 31, 2015

**Peer-review started:** April 1, 2015

**First decision:** June 19, 2015

**Revised:** October 6, 2015

**Accepted:** November 13, 2015

**Article in press:**

**Published online:**

# Abstract

**Aim:** To evaluate the relationship between glutathione S-transferase M1 (GSTM1) polymorphism and susceptibility to esophageal cancer (EC).

**METHODS:** A comprehensive search of the United States National Library of Medicine PubMed database and the Elsevier, Springer, and China National Knowledge Infrastructure databases for all relevant studies was conducted using combinations of the following terms: “glutathione S-transferase M1”, “GSTM1”, “polymorphism”, and “EC” (until November 1, 2014). The statistical analysis was performed using the SAS software (v.9.1.3; SAS Institute, Cary, NC, United States) and the Review Manager software (v.5.0; Oxford, England); crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between the GSTM1 null genotype and the risk of EC.

**RESULTS:** A total of 37 studies involving 2236 EC cases and 3243 controls were included in this meta-analysis. We observed that the GSTM1 null genotype was a significant risk factor for EC in most populations (OR = 1.33, 95%CI: 1.12-1.57, *P*heterogeneity < 0.000001, and *I*2 = 77.0%), particularlyin Asian populations (OR = 1.53, 95%CI: 1.26-1.86, *P*heterogeneity < 0.000001, and *I*2 = 77.0%), but not in the Caucasian population(OR = 1.02, 95%CI: 0.87-1.19, *P*heterogeneity = 0.97, and *I*2 = 0%).

**CONCLUSION:**The GSTM1 null polymorphism may be associated with an increased risk for EC in Asian but not Caucasian populations.

**Key words:** Meta-analysis; glutathione S-transferase M1; Polymorphism; Esophageal cancer; Deletions

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Many previous studies have investigated the association between the glutathione S-transferase M1 (GSTM1) null genotype and the risk of esophageal cancer (EC), but these studies have provided controversial findings. The present study represents the largest meta-analysis to estimate the association between the GSTM1 polymorphism and EC risk. We investigated these two genotypes (GSTM1null or GSTM1 present) in terms of EC morbidity.

Lu QJ, Bo YC, Zhao Y, Zhao EJ, Sapa WB, Yao MJ, Duan DD, Zhu YW, Lu WQ, Yuan L. Glutathione S-transferase M1 polymorphism and esophageal cancer risk: An updated meta-analysis based on 37 studies. *World J Gastroenterol* 2015; In press

# Introduction

Esophageal cancer (EC), which is the sixth leading cause of malignancies worldwide, has two major histological types: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EADC)[[1](#_ENREF_1)]. Additionally, the five-year survival rate is less than 20%[[2](#_ENREF_2)]. A growing body of epidemiological evidence suggests that environmental factors together with genetic factors play important roles in the risk of developing esophageal carcinoma[[3](#_ENREF_3),[4](#_ENREF_4)]. The major risk factors for EC include alcohol consumption, smoking tobacco, and micronutrient deficiency[[5](#_ENREF_5)]. Various factors and multiple processes lead to EC development. In addition to the above mentioned factors, genetic factors also account for EC cases.

Previous studies have suggested that glutathione S-transferases (GSTs) are phase II metabolizing enzymes that detoxify free radicals and other carcinogens[[6](#_ENREF_6)]. Therefore, individuals variation in Phases II enzyme activity may contribute to varying susceptibility to EC progression. The GST family plays an important role in the detoxification of a variety of electrophilic carcinogens through conjugation with glutathione, and there is a widely variable organ distribution of the four classes of GSTs, although all of these display esophageal expression: GSTA (a), GSTM (m), GSTP (p), and GSTT (h)[[7](#_ENREF_7),[8](#_ENREF_8)]. Homozygous deletions of GSTM1 have been associated with the loss of enzymatic activity for the detoxification of carcinogens, which consequently confersa risk for some cancers, such as colorectal, pancreatic, esophageal, and head and neck cancers[[9-12](#_ENREF_9)]. Therefore, the null genotype of GSTM1 might be associated with an increased risk of EC[[13](#_ENREF_13)]. Many previous studies have investigated the association between the GSTM1 null genotype and the risk of esophageal carcinoma, but these studies have provided controversial findings[[8](#_ENREF_8),[14-18](#_ENREF_14)]. It remains uncertain whether the GSTM1 polymorphism is a risk factor for EC. Considering these controversial results, we conducted a meta-analysis summarizing reported case–control or prospective studies to assess the risk of EC.

# Materials and methods

## *Search strategy*

We conducted a comprehensive search of the US National Library of Medicine PubMed database and the Elsevier, Springer, and China National Knowledge Infrastructure databases for all relevant studies using combinations of the following terms: “glutathione S-transferase M1”, “GSTM1”, “polymorphism”, and “EC” (until November 1, 2014). Additional eligible studies were identified through references that were cited in the relevant articles. The full text of each potentially relevant paper was scrutinized to ensure that the following inclusion criteria were met: (1) the articles clearly described studies concerning the association of EC with GSTM1 polymorphisms; (2) The study design should be observational (case–control or prospective) designs; (3) Sufficient data for estimating the odds ratios (ORs) and 95% confidence intervals (CIs)were present; and (4) If more than one publication reported on the same population, we selected the study with the largest sample size.

## *Data extraction*

Two researchers independently extracted the following data from each study that met the inclusion criteria: first author’s surname, year of publication, country, ethnicity of the subjects (stratified into Asian, Caucasian, and African populations), sources of the controls (categorized as population-based studies and hospital-based studies), histological type (adenocarcinoma and squamous cell carcinoma), number of different genotypes in cases and controls, smoking status, and the frequency of different genotypes in the cases and controls. Individuals with “present” genotype wwere defined as carriers with at least one of the functional alleles in accordance with the definition used in most studies, whereas individuals carrying none of the alleles were classified as the “null” genotype.

## *Statistical analysis*

Crude ORs with 95% CIs were used to estimate the strength of the relationship between the GSTM1 polymorphism and EC risk. The pooled ORs were evaluated for null *vs* present genotypes. The heterogeneity was assessed using a chi-square analysis based on the *Q*-test[[19](#_ENREF_19)]. The heterogeneity was considered significant for *P* < 0.05. In the presence of significant heterogeneity, a random-effect model (the DerSimonian and Laird method)[[20](#_ENREF_20)] was used to calculate pooled estimates; otherwise, a fixed-effect model (the Mantel–Haenszel method) was used[[21](#_ENREF_21)]. These two models provided similar results in the absence of heterogeneity. The potential publication bias was assessed using a funnel plot and linear regression asymmetry test[[22](#_ENREF_22)].The statistical analyses were performed using the SAS(v.9.1.3; SAS Institute, Cary, NC, United States) and Review Managersoftware (v.5.0; Oxford, England) with two-sided *P* values and a 0.05 significance level.

# Results

## *Eligible studies*

A total of 37 studies involving 2236 EC cases and 3243 controls were finallyincluded in this meta-analysis[[8](#_ENREF_8),[12-18](#_ENREF_12),[23-51](#_ENREF_23)]. The main characteristics of these studies are presented in Table 1. Among these studies, one case–control study was nested within a cohort study[[51](#_ENREF_51)], and 25 studies provided data of the histological type of the EC cases. The smoking statuses of the cases and controls were recorded in six studies.

## *Meta-analysis*

Considering the obvious heterogeneity among the 37 included studies (*P* < 0.001, *I*2 = 77%), the random effect model (DerSimonian–Laird method) was used to calculate the pooled ORs for the GSTM1 null *vs* GSTM1present genotypes. Individuals with GSTM1 null genotypes were significantly associated with an increased risk for EC compared those carrying the GSTM1present genotype (OR = 1.33, 95%CI: 1.12-1.57, Figure 1). In the sensitivity analysis, individual studies were sequentially removed. The results indicated that no individual study significantly affected the pooled OR, suggesting that these results were statistically robust.

In the subgroup analysis based on ethnicity, a positive correlation was observed between the GSTM1 null genotype and the EC risk in the Asian population (OR = 1.53, 95%CI: 1.26-1.86) but not in the Caucasianpopulation (OR = 1.02, 95%CI: 0.87-11.19). However, the results of the stratified analysis based on histological typeshowed that the GSTM1 null genotype increased the risk of EC in patients whose histological types were unknown, but no statistically significant association was observed for either the ESCC patients or the EADC patients. Moreover, the heterogeneity was significantly reduced among Caucasian populations and studies based on the histological type of adenocarcinoma. Because only one study (14EADC, 137 ESCC) reported an association between the GSTM1 polymorphism and EADC in Asian populations, we only analyzedthe data according to ESCC and EADC in Caucasian populations, and the results showed no statistically significant association between the GSTM1 polymorphism and ESCC or EADC. The main results of this meta-analysis and the heterogeneity test are shown in Table 2.

## *Publication bias*

A funnel plot was used to graphically estimate the publication bias of the literature. As shown in Figure 2, the shape of the funnel plot was symmetrical in the overall population, suggesting the absence of publication bias. The results of Egger’s test showed statistical evidence for funnel plot symmetry (*t* = 1.76, *P* = 0.0873).

# Discussion

GSTM1 is a member of the family of cytosolic GSTs, which are phase II xenobiotic-metabolizing enzymes. These enzymes play a crucial role in the detoxification and elimination of electrophilic carcinogens through conjugation with glutathione[[12](#_ENREF_12)]. Many studies have investigated the association between the GSTM1 null genotype and various types of cancer, such as colorectal carcinoma, lung cancer, liver cancer, and EC, but the findings are controversial, particularly those obtained for EC[[52](#_ENREF_52),[53](#_ENREF_53)]. The results of this meta-analysis showed that the GSTM1 null genotype is significantly associated with an increased risk of EC in the overall population. Furthermore, in the subgroup analysis by ethnicity, we detected a significant association between the GSTM1 polymorphism and EC risk in Asians but not in Caucasians, suggesting that the GSTM1 null polymorphism might contribute to increased susceptibility to EC in Asians. Similar results have been obtained in several previous meta-analyses[[54](#_ENREF_54),[55](#_ENREF_55)]. However, other studies have shown conflicting results. A pooled analysis of 20 studies from the Archives of Medical Research revealed that there was no evidence of increased risk of EC associated with the GSTM1 null genotype[[56](#_ENREF_56)]. The result might reflect a relatively small sample size and, to a lesser extent, different ethnicities, different histological types and the source of the controls.

In the present meta-analysis, most of the included studies concerned Asian populations. This phenomenon might be attributed to the occurrence of EC, whichdisplays a remarkable geographical difference. Specifically,the ‘‘EC belt’’, which stretches from North Central China westward through Central Asia and northern Iran, exhibits a particularly high EC incidence in Asian populations[[57](#_ENREF_57)], which explains why many of the studies were conducted in Asian countries.

In the subgroup analysis based on histological type, no significant association was detected between the GSTM1 polymorphism and ESCC or EADC risk, indicating that histological type mightaffect the statistical correlation between the GSTM1 polymorphism and EC. Similar results have been reported in previous studies[[23](#_ENREF_23),[55](#_ENREF_55),[58](#_ENREF_58)], indicating that further clarification of the histological type might avoid the interference of some confounding factors.

Several potential limitations of the present meta-analysis should also be acknowledged. Only one of the included studies study was conducted in Africa, and it did not provide sufficient data for the subgroup analysis based on ethnicity. Therefore, we could not include the African population in the subgroup analysis based on ethnicity. Moreover, only published studies were included in the present meta-analysis, which might have biased the results.

In conclusion, this meta-analysis demonstrated that the GSTM1 null polymorphism might be associated with an increased risk for EC in Asian populations but not in Caucasian populations. Larger well-designed epidemiological studies are warranted to verify these findings.

# Comments

***Background***

Esophageal cancer (EC), which is the sixth leading cause of malignancies worldwide, has two major histological types: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Moreover, its five-year survival rate is less than 20%. Previous studies have suggested that glutathione S-transferase (GSTs) are phase II metabolizing enzymes that detoxify free radicals and other carcinogens. Therefore, individuals with low phase II activity might have a higher risk of developing cancer. The GST family plays an important role in the detoxification of a variety of electrophilic carcinogens through conjugation with glutathione, and there is a widely variable organ distribution of the four classes of GSTs, namely GSTA (a), GSTM (m), GSTP (p), and GSTT(h), present a widely variable organ distribution, although all show esophageal expression.

***Research frontiers***

A growing body of epidemiological evidence suggests that environmental factors together with genetic factors play important roles in the risk of developing esophageal carcinoma: alcohol consumption, smoking tobacco, and micronutrient deficiency are considered the major risk factors for EC. The GSTM1 null genotype has been associated with an increased risk of EC. Many previous studies have investigated the association between the GSTM1 null genotype and the risk of esophageal carcinoma, but these studies provide controversial findings.

***Innovations and breakthroughs***

The results of the present study indicated that the GSTM1 null polymorphism mightbe associated with an increased risk of EC in Asian populations but not in Caucasian populations, which would be helpful for the identification of individuals at an increased risk of developing EC.

***Applications***

The present study enhances the current understanding of the effects of GSTM1 on EC. Larger well-designed epidemiological studies are warranted to confirm the precise mechanism underlying the involvement of the GSTM1 gene in EC progression.

***Terminology***

GSTM1 is a primary member of the GST family, which comprises enzymes that play important roles in the detoxification of a variety of electrophilic carcinogens through conjugation with glutathione. Homozygous deletions of GSTM1 might disrupt enzymatic detoxification of carcinogens and consequently confer risk for some cancers, such as colorectal, pancreatic, esophageal, and head and neck cancers.

***Peer-review***

The present study analyzed the effect of the GST1 polymorphism on EC risk. The meta-analysis of 37 studies showed that the GSTM1 null polymorphism is associated with a significantly increased risk of EC.

# REFERENCES

1 **Cai Y**, Wang J. Significant association of glutathione S-transferase T1 null genotype with esophageal cancer risk: a meta-analysis. *Mol Biol Rep* 2013; **40**: 2397-2403 [PMID: 23238916 DOI: 10.1007/s11033-012-2320-6]

2 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

3 **Denlinger CE**, Thompson RK. Molecular basis of esophageal cancer development and progression. *Surg Clin North Am* 2012; **92**: 1089-1103 [PMID: 23026271 DOI: 10.1016/j.suc.2012.07.002]

4 **Zheng S**, Vuitton L, Sheyhidin I, Vuitton DA, Zhang Y, Lu X. Northwestern China: a place to learn more on oesophageal cancer. Part two: gene alterations and polymorphisms. *Eur J Gastroenterol Hepatol* 2011; **23**: 1087-1099 [PMID: 22002005 DOI: 10.1097/MEG.0b013e32834a14d9]

5 **Hongo M**, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. *J Gastroenterol Hepatol* 2009; **24**: 729-735 [PMID: 19646015 DOI: 10.1111/j.1440-1746.2009.05824.x]

6 **Hayes JD**, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. *Crit Rev Biochem Mol Biol* 1995; **30**: 445-600 [PMID: 8770536 DOI: 10.3109/10409239509083491]

7 **Di Pietro G**, Magno LA, Rios-Santos F. Glutathione S-transferases: an overview in cancer research. *Expert Opin Drug Metab Toxicol* 2010; **6**: 153-170 [PMID: 20078251 DOI: 10.1517/17425250903427980]

8 **Dura P**, Salomon J, Te Morsche RH, Roelofs HM, Kristinsson JO, Wobbes T, Witteman BJ, Tan AC, Drenth JP, Peters WH. No role for glutathione S-transferase genotypes in Caucasian esophageal squamous cell or adenocarcinoma etiology: an European case-control study. *BMC Gastroenterol* 2013; **13**: 97 [PMID: 23731957 DOI: 10.1186/1471-230x-13-97]

9 **Duell EJ**, Holly EA, Bracci PM, Wiencke JK, Kelsey KT. A population-based study of the Arg399Gln polymorphism in X-ray repair cross- complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. *Cancer Res* 2002; **62**: 4630-4636 [PMID: 12183419]

10 **Economopoulos KP**, Sergentanis TN. GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: a comprehensive meta-analysis. *Eur J Cancer* 2010; **46**: 1617-1631 [PMID: 20207535 DOI: 10.1016/j.ejca.2010.02.009]

11 **Lourenço GJ**, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. *Tumour Biol* 2011; **32**: 1209-1215 [PMID: 21870186 DOI: 10.1007/s13277-011-0224-z]

12 **Moaven O**, Raziee HR, Sima HR, Ganji A, Malekzadeh R, A'rabi A, Abdollahi A, Memar B, Sotoudeh M, Naseh H, Nekoui N, Razavipour A, Gholamin M, Dadkhah E, Farshchian M, Abbaszadegan MR. Interactions between Glutathione-S-Transferase M1, T1 and P1 polymorphisms and smoking, and increased susceptibility to esophageal squamous cell carcinoma. *Cancer Epidemiol* 2010; **34**: 285-290 [PMID: 20409775 DOI: 10.1016/j.canep.2010.03.009]

13 **Sharma A**, Das BC, Sehgal A, Mehrotra R, Kar P, Sardana S, Phukan R, Mahanta J, Purkayastha J, Saxena S, Kapur S, Chatterjee I, Sharma JK. GSTM1 and GSTT1 polymorphism and susceptibility to esophageal cancer in high- and low-risk regions of India. *Tumour Biol* 2013; **34**: 3249-3257 [PMID: 23749488 DOI: 10.1007/s13277-013-0897-6]

14 **Tan W**, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF, Lin DX. Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. *Cancer Epidemiol Biomarkers Prev* 2000; **9**: 551-556 [PMID: 10868687 DOI: 10.1007/s00384-001-0383-2]

15 **Yokoyama A**, Kato H, Yokoyama T, Tsujinaka T, Muto M, Omori T, Haneda T, Kumagai Y, Igaki H, Yokoyama M, Watanabe H, Fukuda H, Yoshimizu H. Genetic polymorphisms of alcohol and aldehyde dehydrogenases and glutathione S-transferase M1 and drinking, smoking, and diet in Japanese men with esophageal squamous cell carcinoma. *Carcinogenesis* 2002; **23**: 1851-1859 [PMID: 12419833 DOI: 10.1093/carcin/23.11.1851]

16 **Li D**, Dandara C, Parker MI. The 341C/T polymorphism in the GSTP1 gene is associated with increased risk of oesophageal cancer. *BMC Genet* 2010; **11**: 47 [PMID: 20540773 DOI: 10.1186/1471-2156-11-47]

17 **Chen Y**, Zhang H, Yin D, Wang H, Wang Y, Deng Y, Ma Y. Relationship between GSTM1 gene polymorphism and interaction of gene environment and susceptibility of esophageal cancer. *Xiandai Yufang Yixue* 2012; **39**: 110-113

18 **Djansugurova LB**, Perfilyeva AV, Zhunusova GS, Djantaeva KB, Iksan OA, Khussainova EM. The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan. *Front Genet* 2013; **4**: 70 [PMID: 23675381 DOI: 10.3389/fgene.2013.00070]

19 **Lau J**, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. *Ann Intern Med* 1997; **127**: 820-826 [PMID: 9382404 DOI: 10.7326/0003-4819-127-9-199711010-00008]

20 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833 DOI: 10.1016/0197-2456(86)90046-2]

21 **Mantel N**, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959; **22**: 719-748 [PMID: 13655060]

22 **Egger M**, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**: 629-634 [PMID: 9310563 DOI: 10.1136/bmj.315.7109.629]

23 **Zendehdel K**, Bahmanyar S, McCarthy S, Nyren O, Andersson B, Ye W. Genetic polymorphisms of glutathione S-transferase genes GSTP1, GSTM1, and GSTT1 and risk of esophageal and gastric cardia cancers. *Cancer Causes Control* 2009; **20**: 2031-2038 [PMID: 19618282 DOI: 10.1007/s10552-009-9399-7]

24 **Liu R**, Yin L, Pu Y, Li Y, Liang G, Zhang J, Li X. Functional alterations in the glutathione S-transferase family associated with enhanced occurrence of esophageal carcinoma in China. *J Toxicol Environ Health A* 2010; **73**: 471-482 [PMID: 20391126 DOI: 10.1080/15287390903523394]

25 **Talukdar FR**, Ghosh SK, Laskar RS, Mondal R. Epigenetic, genetic and environmental interactions in esophageal squamous cell carcinoma from northeast India. *PLoS One* 2013; **8**: e60996 [PMID: 23596512 DOI: 10.1371/journal.pone.0060996]

26 **Malik MA**, Upadhyay R, Mittal RD, Zargar SA, Mittal B. Association of xenobiotic metabolizing enzymes genetic polymorphisms with esophageal cancer in Kashmir Valley and influence of environmental factors. *Nutr Cancer* 2010; **62**: 734-742 [PMID: 20661821 DOI: 10.1080/01635581003605904]

27 **Lin DX**, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar FF. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. *Cancer Epidemiol Biomarkers Prev* 1998; **7**: 1013-1018 [PMID: 9829710]

28 **Lu XM**, Zhang YM, Lin RY, Arzi G, Wang X, Zhang YL, Zhang Y, Wang Y, Wen H. Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang, China. *World J Gastroenterol* 2005; **11**: 3651-3654 [PMID: 15968714 DOI: 10.3748/wjg.v11.i24.3651]

29 **Rossini A**, Rapozo DC, Soares Lima SC, Guimarães DP, Ferreira MA, Teixeira R, Kruel CD, Barros SG, Andreollo NA, Acatauassú R, Matos HJ, Albano RM, Pinto LF. Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population. *Carcinogenesis* 2007; **28**: 2537-2542 [PMID: 17916905 DOI: 10.1093/carcin/bgm222]

30 **van Lieshout EM**, Roelofs HM, Dekker S, Mulder CJ, Wobbes T, Jansen JB, Peters WH. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. *Cancer Res* 1999; **59**: 586-589 [PMID: 9973204]

31 **Hori H**, Kawano T, Endo M, Yuasa Y. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. *J Clin Gastroenterol* 1997; **25**: 568-575 [PMID: 9451664 DOI: 10.1097/00004836-199712000-00003]

32 **Jain M**, Kumar S, Rastogi N, Lal P, Ghoshal UC, Tiwari A, Pant MC, Baiq MQ, Mittal B. GSTT1, GSTM1 and GSTP1 genetic polymorphisms and interaction with tobacco, alcohol and occupational exposure in esophageal cancer patients from North India. *Cancer Lett* 2006; **242**: 60-67 [PMID: 16338071 DOI: 10.1016/j.canlet.2005.10.034]

33 **Abbas A**, Delvinquiere K, Lechevrel M, Lebailly P, Gauduchon P, Launoy G, Sichel F. GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma. *World J Gastroenterol* 2004; **10**: 3389-3393 [PMID: 15526353 DOI: 10.3748/wjg.v10.i23.3389]

34 **Li Y**, Zhu W, Lin Z, Wu H, Ye Z. Correlation between smoking and the polymorphism of gene GSTM1 and esophageal carcinoma. *Heilongjiang Yixue Zazhi* 2008; **32**: 18-20

35 **Yin L**, Pu Y, Zhu Z, Hu X, Liu Y, Kai H. Polymorphisms of susceptible genes for esophageal cancer risk in Huaian population in Jiangsu Province. *Tumor* 2005; **25**: 357-367

36 **Shao G**, Hu Z, Li E, Li J, Wen B. Relationship between the GSTM1 genetic polymorphism and susceptibility to squamous cell carcinoma of esophagus. *Shantou Daxue Yixueyuan Xuebao* 1999; **12**: 1-2

37 **Gao P**, Tian Y, Ye X, Ge J, Zhang D, Xu W. Study of CTPIA1, GSTT1, GSTM1 polymorphisms and susceptibility on esophageal carcinoma in Ningxia Hui nationality. *Ningxia Yixue Zazhi* 2012; **34**: 196-199

38 **Ji R**, Wu Jg, ZHou Y, ZHANG B, ZHANG Z, Yang Z. Relationship between CYP1A1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility of esophageal cancer in Wuwei, Gansu Province. *Lanzhou Daxue Xuebao* (Yixueban) 2010; **36**: 29-34

39 **HAN Y**, FENG X, LI P, Niu Z. Case-control study of relationship of CYP1A1 and GSTM1 polymorphisms and susceptibility to esophageal squamous carcinoma. *Zhongguo Gonggong Weisheng* 2005; **21**: 3-6

40 **Shi Y**, Zhou X, Zhou Y, Ren S. Analysis of CYP2E1, GSTM1 genetic polymorphisms in relation to human lung cancer and esophageal carcinoma. *Huazhong Keji Daxue Xuebao* 2002; **31**: 14-17

41 **Wideroff L**, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, Chow WH. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. *Cancer Detect Prev* 2007; **31**: 233-236 [PMID: 17646057 DOI: 10.1016/j.cdp.2007.03.004]

42 **Gao CM**, Takezaki T, Wu JZ, Li ZY, Liu YT, Li SP, Ding JH, Su P, Hu X, Xu TL, Sugimura H, Tajima K. Glutathione-S-transferases M1 (GSTM1) and GSTT1 genotype, smoking, consumption of alcohol and tea and risk of esophageal and stomach cancers: a case-control study of a high-incidence area in Jiangsu Province, China. *Cancer Lett* 2002; **188**: 95-102 [PMID: 12406553 DOI: 10.1016/s0304-3835(02)00115-5]

43 **Nimura Y**, Yokoyama S, Fujimori M, Aoki T, Adachi W, Nasu T, He M, Ping YM, Iida F. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. *Cancer* 1997; **80**: 852-857 [PMID: 9307183 DOI: 10.1002/(sici)1097-0142(19970901)80:5<852::aid-cncr4>3.0.co;2-n]

44 **Wang AH**, Sun CS, Li LS, Huang JY, Chen QS, Xu DZ. Genetic susceptibility and environmental factors of esophageal cancer in Xi'an. *World J Gastroenterol* 2004; **10**: 940-944 [PMID: 15052670]

45 **Casson AG**, Zheng Z, Porter GA, Guernsey DL. Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. *Cancer Detect Prev* 2006; **30**: 423-431 [PMID: 17064856 DOI: 10.1016/j.cdp.2006.09.005]

46 **Liu L**. The relationship between CYPIA1，GSTT1, GSTM1,GSTP1 genetic Polymorphisms and susceptibility of Ningxia Han People esophageal carcinoma. Ningxia Medical University, 2013. Available from: URL: http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=0&CurRec=1&recid=&filename=1013046360.nh&dbname=CMFD201401&dbcode=CMFD&pr=&urlid=&yx=&v=MDYzMzRxVHJXTTFGckNVUkwrZVorVnZGeW5rVkwzUFZGMjZIYk84R05MS3I1RWJQSVI4ZVgxTHV4WVM3RGgxVDM=

47 **Dong CX**, Wu J, Jin Y, Zhang J. Correlation between genetic polymorphism of CYP2E1, GSTM1 and esophageal cancer in Gansu. *Weichangbingxue and Ganbingxue Zazhi* 2007; **16**: 115-118

48 **Casson AG**, Zheng Z, Chiasson D, MacDonald K, Riddell DC, Guernsey JR, Guernsey DL, McLaughlin J. Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. *Cancer Detect Prev* 2003; **27**: 139-146 [PMID: 12670526 DOI: 10.1016/s0361-090x(03)00033-3]

49 **Morita S**, Yano M, Shiozaki H, Tsujinaka T, Ebisui C, Morimoto T, Kishibuti M, Fujita J, Ogawa A, Taniguchi M, Inoue M, Tamura S, Yamazaki K, Kikkawa N, Mizunoya S, Monden M. CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus. *Int J Cancer* 1997; **71**: 192-195 [PMID: 9139841 DOI: 10.1002/(SICI)1097-0215(19970410)71:2<192::AID-IJC11>3.0.CO;2-K]

50 **Wang LD**, Zheng S, Liu B, Zhou JX, Li YJ, Li JX. CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: study of population from a high- incidence area in north China. *World J Gastroenterol* 2003; **9**: 1394-1397 [PMID: 12854128]

51 **Roth MJ**, Abnet CC, Johnson LL, Mark SD, Dong ZW, Taylor PR, Dawsey SM, Qiao YL. Polymorphic variation of Cyp1A1 is associated with the risk of gastric cardia cancer: a prospective case-cohort study of cytochrome P-450 1A1 and GST enzymes. *Cancer Causes Control* 2004; **15**: 1077-1083 [PMID: 15801491 DOI: 10.1007/s10552-004-2233-3]

52 **Darazy M**, Balbaa M, Mugharbil A, Saeed H, Sidani H, Abdel-Razzak Z. CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer among Lebanese. *Genet Test Mol Biomarkers* 2011; **15**: 423-429 [PMID: 21385088 DOI: 10.1089/gtmb.2010.0206]

53 **Yadav DS**, Devi TR, Ihsan R, Mishra AK, Kaushal M, Chauhan PS, Bagadi SA, Sharma J, Zamoawia E, Verma Y, Nandkumar A, Saxena S, Kapur S. Polymorphisms of glutathione-S-transferase genes and the risk of aerodigestive tract cancers in the Northeast Indian population. *Genet Test Mol Biomarkers* 2010; **14**: 715-723 [PMID: 20854097 DOI: 10.1089/gtmb.2010.0087]

54 **Zhong S**, Zhao W, Lu C, Li B, Yuan Y, Guo D, Chang Z, Jiao B, Yang L. Glutathione S-transferase M1 null genotype contributes to increased risk of esophageal carcinoma in Chinese population. *Tumour Biol* 2013; **34**: 2403-2407 [PMID: 23625656 DOI: 10.1007/s13277-013-0790-3]


55 **Zhang C**, Chai Y, Wang P, Yun Y, Dai L, Wang K, Zhang J. Meta-analysis on glutathione S-transferase M1 polymorphisms and the risk of esophageal cancer. *Zhongguo Gonggong Weisheng* 2011; **27**: 241-243

56 **Zhuo WL**, Zhang YS, Wang Y, Zhuo XL, Zhu B, Cai L, Chen ZT. Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. *Arch Med Res* 2009; **40**: 169-179 [PMID: 19427967 DOI: 10.1016/j.arcmed.2009.01.003]


57 **Akbari MR**, Malekzadeh R, Nasrollahzadeh D, Amanian D, Sun P, Islami F, Sotoudeh M, Semnani S, Boffeta P, Dawsey SM, Ghadirian P, Narod SA. Familial risks of esophageal cancer among the Turkmen population of the Caspian littoral of Iran. *Int J Cancer* 2006; **119**: 1047-1051 [PMID: 16570268 DOI: 10.1002/ijc.21906]

58 **Bull LM**, White DL, Bray M, Nurgalieva Z, El-Serag HB. Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. *Dis Esophagus* 2009; **22**: 571-587 [PMID: 19222528 DOI: 10.1111/j.1442-2050.2009.00947.x]

**P-Reviewer:** Corrales FJ, Ghiorzo p, Nagahara h **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**



**Figure 1 Forest plot for the association between the glutathione S-transferase M1 polymorphism and esophageal cancer risk.**



**Figure 2 Funnel plot evaluating the risk of publication bias in this meta-analysis.**

**Table 1 Characteristics of the studies included in this meta-analysis**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Ethnicity** | **Country** | **Source of controls** | **Genotype distribution** | | | | |
| **Case** | |  | **Control** | |
| **Null** | **Present** | **Null** | **Present** |
| Morita *et al*[[49](#_ENREF_49)] | 1997 | Asian | Japan | PB | 23 | 30 |  | 55 | 77 |
| Nimura *et al*[[43](#_ENREF_43)] | 1997 | Asian | China | HB | 47 | 42 |  | 63 | 74 |
| Hori *et al*[[31](#_ENREF_31)] | 1997 | Asian | Japan | PB | 41 | 53 |  | 196 | 232 |
| Lin *et al*[[27](#_ENREF_27)] | 1998 | Asian | China | PB | 20 | 25 |  | 21 | 24 |
| Shao *et al*[[36](#_ENREF_36)] | 1999 | Asian | China | HB | 68 | 40 |  | 55 | 57 |
| van Lieshout *et al*[[30](#_ENREF_30)] | 1999 | Caucasian | The Netherland | PB | 17 | 17 |  | 128 | 119 |
| Tan *et al*[[14](#_ENREF_14)] | 2000 | Asian | China | PB | 46 | 104 |  | 76 | 74 |
| Shi *et al*[[40](#_ENREF_40)] | 2002 | Asian | China | HB | 67 | 31 |  | 51 | 69 |
| Yokoyama *et al*[[15](#_ENREF_15)] | 2002 | Asian | Japan | HB | 103 | 131 |  | 321 | 313 |
| Gao *et al*[[42](#_ENREF_42)] | 2002 | Asian | China | PB | 106 | 35 |  | 133 | 90 |
| Casson *et al*[[48](#_ENREF_48)] | 2003 | Caucasian | Canada | PB | 26 | 19 |  | 25 | 20 |
| Wang *et al*[[50](#_ENREF_50)] | 2003 | Asian | China | PB | 27 | 35 |  | 19 | 19 |
| Wang *et al*[[44](#_ENREF_44)] | 2004 | Asian | China | HB | 74 | 53 |  | 44 | 57 |
| Abbas *et al*[[33](#_ENREF_33)] | 2004 | Caucasian | French | PB | 39 | 29 |  | 59 | 61 |
| Roth *et al*[[51](#_ENREF_51)] | 2004 | Asian | China | Nest | 41 | 90 |  | 145 | 309 |
| HAN *et al*[[39](#_ENREF_39)] | 2005 | Asian | China | HB | 46 | 43 |  | 48 | 51 |
| Lu *et al*[[28](#_ENREF_28)] | 2005 | Asian | China | PB | 36 | 68 |  | 4 | 100 |
| Yin *et al*[[35](#_ENREF_35)] | 2005 | Asian | China | HB | 69 | 37 |  | 61 | 45 |
| Casson *et al*[[45](#_ENREF_45)] | 2006 | Caucasian | Canada | HB | 34 | 22 |  | 54 | 41 |
| Jain *et al*[[32](#_ENREF_32)] | 2006 | Asian | India | HB | 39 | 61 |  | 51 | 86 |
| Dong *et al*[[47](#_ENREF_47)] | 2007 | Asian | China | HB | 76 | 44 |  | 51 | 69 |
| Wideroff *et al*[[41](#_ENREF_41)] | 2007 | Caucasian | United States | PB | 37 | 30 |  | 121 | 87 |
| Rossini *et al*[[29](#_ENREF_29)] | 2007 | Caucasian | Brazil | HB | 51 | 74 |  | 99 | 153 |
| Li *et al*[[34](#_ENREF_34)] | 2008 | Asian | China | PB | 77 | 48 |  | 55 | 70 |
| Zendehdel *et al*[[23](#_ENREF_23)] | 2009 | Caucasian | Sweden | PB | 85 | 85 |  | 230 | 239 |
| Ji *et al*[[38](#_ENREF_38)] | 2010 | Asian | China | PB | 111 | 78 |  | 98 | 127 |
| Malik *et al*[[26](#_ENREF_26)] | 2010 | Asian | India | HB | 68 | 67 |  | 79 | 116 |
| Liu *et al*[[24](#_ENREF_24)] | 2010 | Asian | China | PB | 54 | 43 |  | 32 | 65 |
| Moaven *et al*[[12](#_ENREF_12)] | 2010 | Asian | Iran | HB | 65 | 83 |  | 58 | 78 |
| Li *et al*[[16](#_ENREF_16)] | 2010 | Black | Africa | HB | 33 | 206 |  | 80 | 200 |
| Gao *et al*[[37](#_ENREF_37)] | 2012 | Asian | China | HB | 22 | 18 |  | 45 | 35 |
| Chen *et al*[[17](#_ENREF_17)] | 2012 | Asian | China | HB | 68 | 31 |  | 90 | 96 |
| Liu *et al*[[46](#_ENREF_46)] | 2013 | Asian | China | HB | 47 | 63 |  | 74 | 146 |
| Talukdar *et al*[[25](#_ENREF_25)] | 2013 | Asian | India | PB | 44 | 68 |  | 40 | 90 |
| Sharma *et al*[[13](#_ENREF_13)] | 2013 | Asian | India | PB | 129 | 186 |  | 139 | 297 |
| Dura *et al*[[8](#_ENREF_8)] | 2013 | Caucasian | The Netherland | PB | 228 | 204 |  | 318 | 273 |
| Djansugurova *et al*[[18](#_ENREF_18)] | 2013 | Asian | Kazakhstan | PB | 72 | 43 |  | 24 | 76 |

PB: Population-based study; HB: Hospital-based study.

**Table 2 Main results of the pooled odds ratios in this meta-analysis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Null *vs* present** | | | |
| **No. of studies** | **OR** | **95%CI** | ***P*-value** |
| Total | 37 | 1.33 | 1.12-1.57 | 0.00001 |
| Ethnicity |  |  |  |  |
| Asian | 27 | 1.53 | 1.26-1.86 | 0.00001 |
| Caucasian | 8 | 1.02 | 0.87-1.19 | 0.97 |
| Histological type |  |  |  |  |
| ESCC | 22 | 1.15 | 0.91-1.45 | 0.00001 |
| EADC | 8 | 0.98 | 0.81-1.18 | 0.93 |
| NR | 12 | 1.82 | 1.58-2.09 | 0.007 |
| Smoking status |  |  |  |  |
| Smokers | 6 | 0.97 | 0.53-1.77 | 0.00001 |
| Nonsmokers | 6 | 0.97 | 0.57-1.64 | 0.001 |
| Histological type of Caucasian |  |  |  |  |
| ESCC | 5 | 1.15 | 0.91-1.45 | 0.33 |
| EADC | 8 | 0.98 | 0.81-1.18 | 0.93 |

The*P* value for heterogeneity. ESCC: Esophageal squamous cell carcinoma; EADC: Esophageal adenocarcinoma; NR: Not reported.